Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

May

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy

Association of Body Size and Bladder Cancer Risk

5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Can PFAS Exposure Raise ALL Risk?

Atezolizumab in Alveolar Soft Part Sarcoma Long-Term Follow-up